• Tolazoline’s Presynaptic Modulation: New Insights for Airway

  2026-06-20

  Explore Tolazoline as a potent α2-adrenergic receptor antagonist and its nuanced presynaptic role in airway and islet research. This article offers a deep mechanistic analysis, protocol guidance, and unique experimental insights for advanced in vitro studies.

• Toremifene vs Tamoxifen: Evidence from Advanced Breast Cance

  2026-06-19

  This Cochrane review rigorously compares toremifene and tamoxifen as oral selective estrogen receptor modulators for the treatment of advanced breast cancer. The meta-analysis provides clarity on efficacy, safety, and clinical equivalence, informing experimental and translational research design.

• Cholecystokinin Octapeptide Ammonium: Applied Protocols & La

  2026-06-19

  Cholecystokinin octapeptide ammonium (CCK-8 ammonium) empowers advanced research in neurobiology, immunology, and cardiovascular studies with its receptor-specific actions and robust experimental reproducibility. This guide details protocol enhancements, troubleshooting strategies, and real-world applications, bridging bench discovery to actionable workflows for reliable results.

• Phebestin: A Potent Aminopeptidase Inhibitor Against Malaria

  2026-06-18

  This article examines the recent discovery and characterization of phebestin, a bestatin-related aminopeptidase inhibitor with nanomolar antiplasmodial activity. The findings highlight phebestin’s mechanism of action, efficacy across malaria strains, and its translational potential for combating drug-resistant Plasmodium falciparum.

• Deep Learning Reveals Cardiotoxic Drugs via iPSC-CM Screenin

  2026-06-18

  Grafton et al. introduce a scalable phenotypic screening platform that couples deep learning with high-content imaging of iPSC-derived cardiomyocytes to detect drug-induced cardiotoxicity. This approach enhances early identification of compounds with cardiac risk, offering practical advances for cardiac electrophysiology and drug safety research.

• Cardiogreen (Indocyanine Green): Translational Impact in Vas

  2026-06-17

  This thought-leadership article explores how Cardiogreen (Indocyanine Green) bridges the gap between cutting-edge vascular diagnostics and immuno-oncology, leveraging mechanistic insight and strategic guidance to empower translational researchers. Drawing on the latest evidence—including photothermal-CD47 synergy in solid tumors—this piece provides a roadmap for integrating high-purity APExBIO Cardiogreen into innovative protocols, while contrasting its capabilities against traditional diagnostic dyes and standard product pages.

• Mifepristone (RU486): Optimizing Experimental Cancer Researc

  2026-06-17

  Mifepristone (RU486) from APExBIO stands out for its dual utility in reproductive and oncology research. This guide delivers applied workflows, troubleshooting strategies, and protocol enhancements that unlock the full potential of RU486 in cell-based and in vivo assays.

• Strategic Applications of Mavorixafor Hydrochloride in Trans

  2026-06-16

  Explore how Mavorixafor hydrochloride (AMD-070 hydrochloride), a potent and selective CXCR4 antagonist, is transforming translational research on WHIM syndrome, rare immunodeficiencies, and HIV infection. This article blends mechanistic insight, clinical trial outcomes, and workflow guidance, highlighting APExBIO’s unique offering and the cross-domain impact of CXCR4 antagonism.

• Tranexamic Acid in Fibrinolysis Research: Applied Protocols

  2026-06-16

  Tranexamic Acid stands out as a versatile antifibrinolytic agent, empowering researchers to stabilize clots and model hemostasis in advanced wound care and in vitro assays. This article translates recent biomaterial breakthroughs into actionable workflows, highlighting troubleshooting, protocol optimization, and the unique role of APExBIO's high-purity Tranexamic Acid for reproducible results.

• Isoprinosine: Advanced Immunomodulation and Viral Inhibition

  2026-06-15

  Explore Isoprinosine’s immunomodulatory mechanism and its unique role in viral inhibition, including recent breakthroughs in herpesvirus biology. This article provides in-depth scientific analysis, protocol guidance, and direct application insights for researchers using inosine pranobex.

• Amphotericin B (SKU B1885): Data-Driven Solutions for Cell A

  2026-06-15

  This article presents scenario-based, evidence-backed guidance for deploying Amphotericin B (SKU B1885) in cell viability and cytotoxicity assays. It addresses real laboratory challenges—such as assay reproducibility, toxicity management, and vendor selection—while grounding recommendations in quantitative data and validated best practices. Researchers gain actionable insights on optimizing assay performance with APExBIO’s Amphotericin B.

• EphA2 Identified as Synthetic Lethal Target in MYC-Driven TN

  2026-06-14

  This study introduces a chemogenetic screening platform that reveals EphA2 as a synthetic lethal vulnerability in MYC-driven triple-negative breast cancer (TNBC). By identifying selective cytotoxicity of the EphA2 inhibitor ALW-II-41-27, the research offers a promising therapeutic avenue for aggressive MYC-activated TNBC, particularly where direct MYC inhibition is unfeasible.

• Nullscript: A Distinctive Histone Deacetylase Inhibitor for

  2026-06-13

  Nullscript offers researchers a selective HDAC inhibition tool with inactivity in transcriptional facilitation, uniquely suited for dissecting epigenetic mechanisms in cardiac and neurodegenerative models. Its proven efficacy in reducing myocardial infarct size and its sharp mechanistic contrasts with other HDAC inhibitors make it indispensable for advanced in vivo and in vitro workflows.

• Palbociclib (PD0332991): Advanced Workflows in Cancer Modeli

  2026-06-12

  Palbociclib (PD0332991) is redefining cell cycle research by enabling robust G0/G1 arrest and apoptosis induction in complex tumor models. This article details protocol enhancements, assembloid-specific workflows, and troubleshooting strategies that unlock the full potential of this selective CDK4/6 inhibitor from APExBIO.

• ATP Solution Enables High-Fidelity Kinase & mRNA Assays

  2026-06-12

  APExBIO’s ATP Solution (100 mM) sets a new standard for sensitive enzymatic assays—empowering translational workflows from kinase profiling to mRNA therapeutics. Discover protocol refinements and troubleshooting tips that unlock reproducibility in advanced molecular biology.

451 records 14/31 page Previous Next First page 上5页 1112131415 下5页 Last page